penicillamine has been researched along with Substance Withdrawal Syndrome in 4 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and one patients with rheumatoid arthritis were followed prospectively to assess the efficacy and toxicity of therapy with D-penicillamine." | 7.66 | The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. ( Anastassiades, TP; Dwosh, IL; Ford, PM; Kean, WF; Kelly, HG, 1980) |
| "One hundred and one patients with rheumatoid arthritis were followed prospectively to assess the efficacy and toxicity of therapy with D-penicillamine." | 3.66 | The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. ( Anastassiades, TP; Dwosh, IL; Ford, PM; Kean, WF; Kelly, HG, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kean, WF | 1 |
| Dwosh, IL | 1 |
| Anastassiades, TP | 1 |
| Ford, PM | 1 |
| Kelly, HG | 1 |
| Scheinberg, IH | 1 |
| Jaffe, ME | 1 |
| Sternlieb, I | 1 |
| Hawkins, C | 1 |
| Barron, CN | 1 |
| Rubin, LF | 1 |
| Steelman, RL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease[NCT01472874] | 8 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | g/dL (Mean) |
|---|---|
| Once a Day Trientine | 0.52 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | g/dL (Mean) |
|---|---|
| Once a Day Trientine | 0.54 |
Alanine transaminase (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | U/L (Mean) |
|---|---|
| Once a Day Trientine | 50.89 |
Alanine transaminase (NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | U/L (Mean) |
|---|---|
| Once a Day Trientine | 41.38 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24h (Mean) |
|---|---|
| Once a Day Trientine | 0.52 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24h (Mean) |
|---|---|
| Once a Day Trientine | 0.54 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 313.4 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 287.9 |
The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | international normalized ratio (Mean) |
|---|---|
| Once a Day Trientine | 1.05 |
The International Normalized Ratio (INR) is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy (NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | international normalized ratio (Mean) |
|---|---|
| Once a Day Trientine | 0.99 |
(NCT01472874)
Timeframe: Months 1,2,3,6,9,12 (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 2214 |
(NCT01472874)
Timeframe: Pre Treatment (mean)
| Intervention | mcg/24hr (Mean) |
|---|---|
| Once a Day Trientine | 1959 |
4 other studies available for penicillamine and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Child; Digestive System; Dose-R | 1980 |
The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.
Topics: Ethylenediamines; Female; Hepatolenticular Degeneration; Humans; Male; Middle Aged; Patient Complian | 1987 |
Reaction to D-penicillamine in rheumatoid arthritis.
Topics: Analgesics; Arthritis, Rheumatoid; Humans; Penicillamine; Substance Withdrawal Syndrome | 1973 |
Chlorpromazine and the eye of the dog. IV. Reversibility of ocular lesions.
Topics: Animals; Chlorpromazine; Cornea; Cytoplasmic Granules; Dogs; Eye Diseases; Female; Humans; Male; Pen | 1972 |